Tanaka Yoshiya
The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Rheumatology (Oxford). 2025 Mar 1;64(Supplement_2):ii9-ii14. doi: 10.1093/rheumatology/keaf003.
The RF is a representative autoantibody against the crystallizable fragment (Fc) of denatured IgG that is primarily detected in patients with RA. Although five types of TNF inhibitors can be used to treat RA, no guidelines are available for selecting the appropriate inhibitor for treatment. High serum RF levels are associated with high disease activity, progressive joint destruction, life prognosis associated with organ damage, decreased treatment responsiveness to TNF inhibitors and other drugs and low treatment retention rates. Meanwhile, certolizumab pegol (CZP), a TNF inhibitor without the Fc region, remains at high concentrations in the blood. Unlike other antibody drugs with the Fc region, CZP maintains efficacy in patients with high serum RF levels. When serum IgM-RF levels are high, antibody drugs with the Fc region are more likely to bind to IgM-RF and be degraded. Thus, CZP without the Fc region may be more favourable for patients with high serum RF levels.
类风湿因子(RF)是一种针对变性IgG可结晶片段(Fc)的代表性自身抗体,主要在类风湿关节炎(RA)患者中检测到。尽管有五种类型的肿瘤坏死因子(TNF)抑制剂可用于治疗RA,但尚无选择合适抑制剂进行治疗的指南。血清RF水平高与疾病活动度高、进行性关节破坏、与器官损害相关的生命预后、对TNF抑制剂和其他药物的治疗反应性降低以及治疗保留率低有关。同时,聚乙二醇化赛妥珠单抗(CZP)是一种不含Fc区域的TNF抑制剂,在血液中保持高浓度。与其他含Fc区域的抗体药物不同,CZP在血清RF水平高的患者中仍保持疗效。当血清IgM-RF水平高时,含Fc区域的抗体药物更有可能与IgM-RF结合并被降解。因此,不含Fc区域的CZP可能对血清RF水平高的患者更有利。